



YOUNG ONCOLOGIST CLUB

XII

INTERNATIONAL MEETING OF
YOUNG ONCOLOGIST CLUB

Transforming Cancer Care Therapy: Art Meets Science

Hyatt Regency Pravets, May 9-10, 2025

PROGRAMME

FRIDAY, MAY 9, 2025 (DAY 1)

Hall Pravets

10.45 - 11.00 Conference opening / Welcome addresses - Young Oncologist Club Bulgaria, Balkan Investigation Network of Oncology, European Chinese Alliance of Oncology

LUNG CANCER SESSION

Moderators: Chr. Manegold & P. Balikova & G. Ganev

11.00 - 11.15 New Personalised Treatment of Lung Cancer, S. Baka

11.15 - 11.45 Challenges for Pathologists in Lung Cancer Diagnosis, M. Papotti

11.45 - 12.00 Innovative Diagnostics to Aid the Management of Screening Detected Lung Nodules, W. Voigt

12.00 - 12.15 Resectable Non-Small Cell Lung Cancer: Comparison of Effectiveness for Peri-operative Approaches, L. Piltz

12.15 - 12.35 Adjuvant Treatment for NSCLC, R. Krasteva

12.35 - 12.50 Resectable Non-Small Cell Lung Cancer: Peri-operative Treatment Options, Chr. Manegold

12.50 - 13.05 Clinical Role of 18FDG PET/CT in Differential Diagnosis of Benign and Malignant Positive Lung Lesions, J. Mihailovic

13.05 - 13.30 Precision Immunotherapy: Biomarkers and Individualized Strategy, Chr. Zielinski

13.30 - 14.30 Lunch

14.30 - 14.45 Multiple Cohort, Open-Label, Exploratory Clinical Study of Trilaciclib in Myeloprotection in First-Line Combination Chemotherapy Regimens for Advanced Solid Tumors - Interim Data Analysis, Xuan Su

14.45 - 15.00 Immunotherapy in the Treatment of SCLC, N. Chilingirova

15.00 - 16.00 Interactive Tumor Board - R. Krasteva, J. Arabadjiev, Chr. Manegold, N. Chilingirova, P. Castellucci, B. Iliev, P. Balikova, T. Hadjieva, Z. Zahariev, Ts. Tatarov

Hall Pravets

16.00 – 17.00 Putting the Pieces Together to Optimize the Management of BRAFV600E-mutant Tumors: Interactive Workshop with Clinical Cases for Melanoma and CRC – Pierre Fabre Symposium

- ▶ Let's Put the Puzzle Together in a BRAF Mutant Melanoma with Brain Metastasis

Moderator: A. Konsoulova

- ▶ Assembling the Pieces: How to Optimise Treatment Strategies for BRAFV600E-mutant mCRC

Moderators: R. Krasteva, N. Chilingirova

17.00 – 18.00 Breast and Prostate Cancer: Science and Experience - Novartis Symposium

Moderator: R. Krasteva

- ▶ New Opportunities in Prostate Cancer Treatment, R. Krasteva
- ▶ Pluvicto – The New Perspective, B. Iliev
- ▶ Moving to Breast Cancer, R. Krasteva
- ▶ eBC – Risk of Progression and Treatment Approach, L. Simeonova
- ▶ Clinical Experience with Ribociclib in Uni Hospital – Summary Analysis for the Period from March 2020 to March 2025, S. Nedeva

18.00 – 19.00 Immunotherapeutic Strategies in Gastrointestinal Cancers: Guidelines and Challenges - BMS Symposium

Moderator: R. Krasteva

- ▶ Clinical Case on Advanced Gastric Cancer and Data Supporting from CM649, Tsv. Yordanov
- ▶ Clinical Case on Advanced Esophageal Cancer and Data Supporting from CM649, I. Koleva
- ▶ Data on CRC (CM8HW) and HCC (CM9DW), R. Krasteva

19.00 – 20.00 What's New and What's Unprecedented in mBC and mNSCLC? - Pfizer Symposium

Moderator: R. Krasteva

- ▶ New Data from the Largest Real-World OS Comparison of the Three CDK4/6 Inhibitors + AI, I. Tonev
- ▶ How the Unprecedented 5-years CROWN Data Correspond to the Uni Hospital's Own Experience with Lorlatinib, B. Iliev

20.00 – 23.00 Dinner

Hall Monovets

16.00 – 16.20 Lonquex® (lipegfilgrastim): Building Confidence from Experience, L. Simeonova - Teva Lecture

16.20 – 16.40 New Approaches in the Treatment of Metastatic Colorectal Cancer and Metastatic Cholangiocarcinoma - Servier Lectures

- ▶ The SUNLIGHT Study, Supported by Real-World Data in 3rd Line Treatment of mCRC, S. Nedeva

- ▶ New Therapeutic Approaches in the Treatment of mCCA and IDH1 Mutation, Ts. Yordanov

16.40 – 17.00 Modern Molecular Genetic Analyses in mCRC and their Role in Determining Therapeutic Behavior, N. Tsonev - Amgen Lecture

17.00 – 17.20 NUBEQA: Evolution in the Standard of Treatment for mHSPC, Tsv. Tatarov - Bayer Lecture

17.20 – 17.40 Tecentriq Subcutaneous Formulation (SC) - an Option for Optimizing the Immunotherapy Treatment, B. Iliev - Roche Lecture

Hall Borovets

16.00 – 19.00 Pathology Workshop, M. Pappotti



SATURDAY, MAY 10, 2025 (DAY 2)

Hall Pravets

BREAST CANCER SESSION

Moderators: Al. Gerasimov & A. Fakirova & Y. Yordanov

- 09.00 – 09.15 The Rising Epidemic of Cancer in Younger Adults, F. Zagouri
09.15 – 09.30 Early Breast Cancer - What Is It? Methods of Detection, Surgical Treatment, G. Zografos
09.30 – 10.00 All you Need to Know about the HER2 Updates in Breast Cancer – workshop, S. Popovska, Sv. Batchurska
10.00 – 10.15 Non-FDG PET/CT in Diagnostic of Breast Cancer, R. Mei
10.15 – 10.30 Breast Cancer Management in Bulgaria: Evaluating Routine Practices, Treatment Strategies, and Gaps in Care, G. Dimitrov
10.30 – 10.45 Redefining Hope: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, Shuang You
10.45 – 11.00 Hybrid Sentinel Lymph Node Imaging in Breast Cancer, M. Mihaylova

RADIOTHERAPY SESSION: Looking to the Future...

- 11.00 – 11.15 New Technologies in Radiotherapy – Ride in the Future, Z. Zahariev
11.15 – 11.30 Flash Radiotherapy - Gateway to Promised Land or Another Mirage / How Close Are We to Real Practice? /, T. Hadjieva

OTHER CANCER LOCALIZATIONS SESSION

Moderators: G. Ganev & A. Kontilev & T. Karanikolova

- 11.30 – 11.45 ⁶⁸Ga-FAPI PET Imaging in Oncology, S. Sergieva
11.45 – 12.00 Theranostic Approach in Prostate Cancer P. Castellucci
12.00 – 12.15 Non-FDG PET/CT in Diagnostic Oncology, F. Giammarile
12.15 – 12.30 Advances in Immunotherapy for Prostate Cancer, Yun Bai
12.30 – 13.30 Lunch
13.30 – 14.45 Workshop Young Oncologists Competition – Compare our Knowledge – Interactive Session
14.45 – 15.00 Cancer in Adolescent and Young Adults (AYA) – Current Landscape, Challenges and Unmet Needs. A Clinical Perspective, Tsv. Yordanov, A. Konsoulova
15.00 – 15.15 Neoplastic Complications Related to Breast Implants: Insight into Diagnosis and Treatment of Breast Implant - Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC), Y. Yordanov
15.15 – 15.30 PET/MRI Based Radiomics and Artificial Intelligence in Prostate Cancer Diagnosis, V. Hadzhyiska
15.30 – 15.45 Prostate Cancer - What Does the Pathology Report Show us?, A. Fakirova
15.45 – 16.00 Leadership in Oncology, N. Toromanov

Hall Pravets

16.00 – 17.00 Choosing the Right Treatment for Patients with NSCLC: Current Standard of Care and Future Opportunities - MSD Symposium

Moderator: J. Arabadjiev

- ▶ First-line Treatment of Metastatic NSCLC with Pembrolizumab – Real-World Oncology, R. Krasteva
- ▶ A New Era in ES-NSCLC: Reshaping the Role of Immunotherapy in the Treatment of Early Stage NSCLC, I. Tonev

17.00 – 17.40

- ▶ Johnson&Johnson Drugs for Advanced Prostate Cancer, Al. Gerasimov
- ▶ Rybrevant® - Therapeutic Indications, B. Iliev
Johnson&Johnson Symposium

17.40 – 18.40 EMBARK - Clinical Trial Data and Everyday Practice
Astellas Symposium

Moderator: R. Krasteva

- ▶ Benefits of Early Intensification of nmHSPC, S. Bakalov
- ▶ EMBARK - Xtandi as a Combination with ADT in nmHSPC, M. Nikolov
- ▶ EMBARK - Xtandi as a Monotherapy in nmHSPC, N. Evgeniev

18.40 – 19.40 Who Wants to Be a Trial-ionaire? – Mastering the Essentials of BC, LC, and PC - Astra Zeneca Symposium

- ▶ Advancing Clinical Research in Breast Cancer, I. Tonev
- ▶ Evolving Paradigms in Lung Cancer Trials, B. Iliev
- ▶ Innovations in Prostate Cancer Clinical Trials, K. Koynov

POSTER SESSION 09.00 – 19.00

19.40 – 20.00 Poster Awards

20.00 – 23.00 Dinner

SUNDAY, MAY 11, 2025 (DAY 3)

08.30 – 09.00 Check out of the hotel

Hall Monovetz

16.00 – 16.40 Metastatic Uveal Melanoma – from Diagnosis to Treatment - Medison Symposium

Moderator: Al. Gerasimov

- ▶ The Key to a New Therapeutic Opportunity in Patients with Metastatic Uveal Melanoma is their HLA Status, E. Naumova
- ▶ Emerging New Strategies and Learnings from Tebentafusp in mUM, S. Nedeva

16.40 – 17.00 A New Hope for Patients with Platinum-Resistant Ovarian Cancer: Mirvetuximab Soravtansine, P. Balikova - AbbVie Lecture

17.00 – 17.20 Improving Outcomes with First-Line Maintenance Therapy in Patients with Ia/ mUC: the JAVELIN Bladder 100 Study Supported by Real-World Data, A. Changalova - Merck Lecture

17.20 – 18.20

- ▶ Treatment Approach in HR+, HER2- EBC, with High-Risk and Nodal Involvement - Practical Experience and Efficacy Data in MonarchE Clinical Study, M. Musin
- ▶ Treatment of HR+,HER2- EBC, with High-Risk and Nodal Involvement –Personal Experience Sharing and Safety Data in MonarchE Clinical Study, S. Nedeva
- ▶ Practical Experience Sharing and Treatment Approach in HR+,HER2- MBC, with High-Risk - Efficacy Data in Monarch 2 Clinical Study, I. Kazmoukov

Eli Lilly Symposium

Moderator: I. Tonev